Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.

Objective: To investigate the efficacy and safety of bevacizumab in heavily pretreated patients with recurrent ovarian cancer.

Methods: Patients with recurrent ovarian cancer were treated with intravenous bevacizumab 10 mg/kg every other week plus oral cyclophosphamide 50 mg daily until disease progression or undue toxicity. Adverse events were graded according to the NCI Common Toxicity Criteria.